HealthQuill Basilea Pharmaceuticals
Switzerland’s Basilea Pharmaceutica Ltd. will receive $1.25 million from its partner Pfizer Inc. after the latter exceeded the sales target for a licensed anti-fungal drug in the Asia-Pacific region and China.
Drugs Medical Pharma

Basilea Pharmaceutica to get $1.25m license fee from Pfizer

Switzerland’s Basilea Pharmaceutica Ltd. will receive $1.25 million from its partner Pfizer Inc. after the latter exceeded the sales target for a licensed.

Read More
The USFDA approved Swiss-based Basilea Pharmaceutica International’s Zevtera injection for the treatment of staphylococcus aureus bloodstream infections and skin infections in adults and community-acquired bacterial pneumonia in patients three months to 18 years, and adults. 
Drugs Health Pharma

Swiss-based Basilea Pharmaceutical’s antimicrobial drug gets FDA nod 

HQ Team April 4, 2024: The USFDA approved Swiss-based Basilea Pharmaceutica International’s Zevtera injection for the treatment of staphylococcus aureus bloodstream infections and.

Read More
Swiss biotechnology company, Basilea Pharmaceutica’s last stage trials of ceftobiprole to treat bacterial bloodstream infections have shown favourable outcomes, according to a statement.
Drugs Health Pharma

Swiss firm Basilea reports positive results in late-stage Staph trials

HQ Team September 28, 2023: Swiss biotechnology company, Basilea Pharmaceutica’s last stage trials of ceftobiprole to treat bacterial bloodstream infections have shown favourable.

Read More
X